VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION CAPSULE

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

VITAMIN A (RETINYL PALMITATE); VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)

Διαθέσιμο από:

NUTRICORP INTERNATIONAL

Φαρμακολογική κατηγορία (ATC):

A11JA

INN (Διεθνής Όνομα):

COMBINATIONS OF VITAMINS

Δοσολογία:

200000UNIT; 40UNIT

Φαρμακοτεχνική μορφή:

CAPSULE

Σύνθεση:

VITAMIN A (RETINYL PALMITATE) 200000UNIT; VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 40UNIT

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

500

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

VITAMIN A

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0225696007; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2016-04-06

Αρχείο Π.Χ.Π.

_ _
_Page 1 of 37_
PRODUCT MONOGRAPH
PR
VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION
VITAMIN A AND VITAMIN E SOFTGEL CAPSULES
200,000 IU Vitamin A (all-trans-retinyl palmitate) and 40 IU Vitamin E
(all-rac-alpha-
tocopheryl acetate)
One IU of Vitamin A is equivalent to the activity of 0.3 mcg of
all-trans-retinol
ATC code: Vitamins – A11
Nutricorp International
4025 Rhodes Drive
Windsor, Ontario
N8W 5B5
Date of Preparation:
April 5, 2016
Submission Control No: 167924
_ _
_ _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
.......................................................